Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
17
PLRX Quote, Financials, Valuation and Earnings
Last price:
$1.24
Seasonality move
:
-12.32%
Day range:
$1.19 - $1.24
52-week range:
$1.10 - $14.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.40x
P/B ratio:
0.37x
Volume:
511.4K
Avg. volume:
1.5M
1-year change:
-91.38%
Market cap:
$74.4M
Revenue:
--
EPS (TTM):
-$2.87
Analysts' Opinion
-
Consensus RatingPliant Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.25, Pliant Therapeutics, Inc. has an estimated upside of 168.6% from its current price of $1.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.21.
Fair Value
-
According to the consensus of 6 analysts, Pliant Therapeutics, Inc. has 168.6% upside to fair value with a price target of $3.25 per share.
PLRX vs. S&P 500
-
Over the past 5 trading days, Pliant Therapeutics, Inc. has underperformed the S&P 500 by -1.38% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Pliant Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pliant Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Pliant Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Pliant Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Pliant Therapeutics, Inc. reported earnings per share of -$0.43.
Enterprise value:
-107.6M
EV / Invested capital:
-0.41x
Price / LTM sales:
20.40x
EV / EBIT:
--
EV / Revenue:
-25.74x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
0.68x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.8M
Return On Assets:
-49.75%
Net Income Margin (TTM):
--
Return On Equity:
-66.1%
Return On Invested Capital:
-53.89%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.5M | -- | -- | -- | -- | |
| Gross Profit | -$718K | -$2.1M | -$1.8M | -$532K | -$436K | |
| Operating Income | -$174.5M | -$222.1M | -$186.2M | -$62M | -$28.4M | |
| EBITDA | -$170.2M | -$220M | -$184.4M | -$61.5M | -$27.9M | |
| Diluted EPS | -$2.78 | -$3.34 | -$2.87 | -$0.95 | -$0.43 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $228.6M | $366M | $534.3M | $410M | $245.6M | |
| Total Assets | $234.1M | $377.2M | $540.5M | $445.7M | $276.6M | |
| Current Liabilities | $12.9M | $26.2M | $27.4M | $40M | $17.6M | |
| Total Liabilities | $13.7M | $40.2M | $37.4M | $99.8M | $76.3M | |
| Total Equity | $220.4M | $337M | $503M | $345.8M | $200.3M | |
| Total Debt | -- | $14M | $10M | $59.9M | $58.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$122.5M | -$132.9M | -$158.2M | -$32.3M | -$21.1M | |
| Cash From Investing | -$138.9M | $133.1M | $171.7M | $31M | $27.9M | |
| Cash From Financing | $274.5M | $23.2M | $672K | $543K | $72K | |
| Free Cash Flow | -$123.5M | -$136.6M | -$158.8M | -$33.2M | -$21.1M | |
PLRX
Sector
Market Cap
$74.4M
$28.2M
Price % of 52-Week High
8.5%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
2.87%
-1.54%
1-Year Price Total Return
-91.38%
-18.1%
Beta (5-Year)
1.291
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.23
200-day SMA
Sell
Level
$1.49
Bollinger Bands (100)
Sell
Level
1.38 - 1.7
Chaikin Money Flow
Sell
Level
-1M
20-day SMA
Sell
Level
$1.31
Relative Strength Index (RSI14)
Sell
Level
36.47
ADX Line
Sell
Level
8.51
Williams %R
Neutral
Level
-77.1429
50-day SMA
Sell
Level
$1.52
MACD (12, 26)
Buy
Level
0.33
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Sell
Level
-885.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7705)
Sell
CA Score
(Annual)
Level (-1.099)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.3334)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. It offers a product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, PLRX has received 0 Buy ratings 6 Hold ratings, and 0 Sell ratings. The PLRX average analyst price target in the past 3 months is $3.25.
-
Where Will Pliant Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pliant Therapeutics, Inc. share price will rise to $3.25 per share over the next 12 months.
-
What Do Analysts Say About Pliant Therapeutics, Inc.?
Analysts are divided on their view about Pliant Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pliant Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Pliant Therapeutics, Inc.'s Price Target?
The price target for Pliant Therapeutics, Inc. over the next 1-year time period is forecast to be $3.25 according to 6 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is PLRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pliant Therapeutics, Inc. is a Hold. 6 of 6 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PLRX?
You can purchase shares of Pliant Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pliant Therapeutics, Inc. shares.
-
What Is The Pliant Therapeutics, Inc. Share Price Today?
Pliant Therapeutics, Inc. was last trading at $1.24 per share. This represents the most recent stock quote for Pliant Therapeutics, Inc.. Yesterday, Pliant Therapeutics, Inc. closed at $1.21 per share.
-
How To Buy Pliant Therapeutics, Inc. Stock Online?
In order to purchase Pliant Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PLRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PLRX
Sector
P/E ratio
--
23.92x
PEG ratio
-0.05x
-0.01x
P/B ratio
0.37x
1.83x
Price / LTM sales
20.40x
1.61x
Growth Metrics
PLRX
Sector
Revenue growth
--
4.6%
Earnings growth
54.97%
10.88%
Revenue (5-year growth)
-100%
6.46%
Earnings forecast
-$0.52
-$0.21
Profitability
PLRX
Sector
Profitability FY 2024
-$2.1M
$3.5M
Return on invested capital
-53.89%
-31.84%
Return on assets
-49.75%
-27.96%
Return on equity
-66.1%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
5
Balance Sheet
PLRX
Sector
Total cash
$241.8M
$26.3M
Short term investments
$284.5M
$25.7M
Total assets
$396.9M
$76.9M
Long term debt
$58.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
